Source: Benzinga

Aerpio: SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Aerpio Pharmaceuticals, Inc. Merger

WILMINGTON, Del., May 27, 2021 (GLOBE NEWSWIRE) -- Rigrodsky Law, P.A. announces that it is investigating Aerpio Pharmaceuticals, Inc. ("Aerpio") (NASDAQ GS: ARPO) regarding possible breaches of fiduciary duties and other violations of law related to Aerpio's agreement to merge with Aadi Bioscience, Inc. To learn ...Full story available on Benzinga.com

Read full article »

Aerpio's Competitors | Aerpio's News | Aerpio's Financials

Followers on Owler

Est. Annual Revenue

$5.0-25M

Est. Employees

25-100

President & CEO

Joseph Gardner

CEO Approval Rating

84/100

Aerpio is an Ohio-based biopharmaceutical company that develops and commercializes Tie2-based protein therapeutics for the treatment of ocular diseases.